Marta Ferrer Lozano

Marta Ferrer Lozano

Auto-generated profile, based on publicly available information

Marta Ferrer Lozano


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
ILIsabel Leiva-Gea
Isabel Leiva-Gea
MYM. Yan
M. Yan
RCRoque Cardona-Hernandez
Roque Cardona-Hernandez
MLMarta Ferrer Lozano
Marta Ferrer Lozano
PBPilar Bahíllo-Curieses
Pilar Bahíllo-Curieses
JSJacobo Pérez Sánchez
Jacobo Pérez Sánchez
Objective: To assess the impact of the COVID-19 pandemic and lockdown measures on the presenting characteristics (age at diagnosis, severity, monthly distribution) of newly diagnosed type 1 diabetes in Spanish children. Research Design and Methods: An ambispective observational multicenter study was conducted in nine Spanish tertiary-level hospitals between January 2015 and March 2021. Inclusion criteria: new cases of type 1 diabetes in children (0–14 years) recording age, sex, date of diagnosis, presence of diabetic ketoacidosis (DKA) at onset, and severity of DKA. Data were compared before and during the pandemic. Results: We registered 1444 new cases of type 1 diabetes in children: 1085 in the pre-pandemic period (2015–2019) and 359 during the pandemic (2020–March 2021). There was a significant increase in the group aged ≤4 years in the pandemic period (chi-squared = 10.986, df 2, p = 0.0041). In 2020–2021, cases of DKA increased significantly by 12% (95% CI: 7.2–20.4%), with a higher percentage of moderate and severe DKA, although this increase was not significant. In 2020, there was a sharp decrease in the number of cases in March, with a progressive increase from May through November, higher than in the same months of the period 2015–2019, highlighting the increase in the number of cases in June, September, and November. The first three months of 2021 showed a different trend to that observed both in the years 2015–2019 and in 2020, with a marked increase in the number of cases. Conclusions: A change in monthly distribution was described, with an increase in DKA at onset of type 1 diabetes. No differences were found in severity, although there were differences in the age distribution, with an increase in the number of cases in children under 4 years of age.

1 November 2021 in Anales de Pediatría (English Edition)
Verified
Journal Article
Open access
JAJesús González de Buitrago Amigo
Jesús González de Buitrago Amigo
AGAna González García
Ana González García
PFPaula Díaz Fernández
Paula Díaz Fernández
MLMercedes Fernández Llamas
Mercedes Fernández Llamas
MBMaría Luz Tejado Bravo
María Luz Tejado Bravo
MLMarta Ferrer Lozano
Marta Ferrer Lozano
Post-prandial glucose control is essential to achieve metabolic goals in patients with type 1 diabetes mellitus (T1DM). The new "faster aspart" insulin has a pharmacological profile noted for its faster absorption and onset of action, and increased early availability, resulting in improved blood glucose control after meals. The main objective of the study was to analyse the efficacy of "faster aspart" vs. "insulin aspart" in children and adolescents with DM1 on sensor-augmented pump treatment. Multicentre, longitudinal and prospective analytical trial evaluating the use of faster aspart insulin for three months in children with T1DM with MiniMed640G® sensor-augmented pumps previously treated with aspart insulin. At the beginning and end of the study the following variables were analysed for subsequent comparison: mean sensor glucose, percentage of time in range, hypoglycaemia and hyperglycaemia, area under the curve (AUC) 180 mg/dL, mean sensor glucose pre- and postprandial in main meals, daily insulin requirements, basal/bolus percentage, and HbA1c. Acute complications, adverse events and satisfaction survey were assessed. The study included 32 patients with a mean of 13.49 ± 2.42 years of age and with T1DM of 7.0 ± 3.67 years of onset. The use of faster aspart was associated with lower time in hyperglycaemia >180 mg/dL (25.8 ± 11.3 vs. 22.4 ± 9.5; p = .011) and >250 mg/dL (5.2±4.9 vs. 4.0 ± 3.6; p = .04), lower AUC >180 mg/dL (10.8 ± 6.5 vs. 9.3 ± 6.1; p = .03), and increased time in range (71.4 ± 10.0 vs. 74.3 ± 9.2; p = .03). No significant changes in hypoglycaemia, HbA1c, insulin requirements, and basal/bolus percentages were detected. Faster aspart was safe and well-evaluated by patients and caregivers. Faster aspart achieves better glycaemic control by increasing glucose time in range in children and adolescents with T1DM on treatment with sensor-augmented pumps.

1 June 2020 in Medicina Clinica
Verified
Journal Article
Closed access
PLPilar Caudevilla Lafuente
Pilar Caudevilla Lafuente
AAAntonio de Arriba-Muñoz
Antonio de Arriba-Muñoz
SISilvia Izquierdo
Silvia Izquierdo
MLMarta Ferrer Lozano
Marta Ferrer Lozano
MIMarta Medrano San Ildefonso
Marta Medrano San Ildefonso
JAJosé Ignacio Labarta Aizpún
José Ignacio Labarta Aizpún

1 November 2021 in Anales de Pediatría
Verified
Journal Article
Open access
JAJesús González de Buitrago Amigo
Jesús González de Buitrago Amigo
AGAna González García
Ana González García
PFPaula Díaz Fernández
Paula Díaz Fernández
MLMercedes Fernández Llamas
Mercedes Fernández Llamas
MBMaría Luz Tejado Bravo
María Luz Tejado Bravo
MLMarta Ferrer Lozano
Marta Ferrer Lozano
Post-prandial glucose control is essential to achieve metabolic goals in patients with type 1 diabetes mellitus (T1DM). The new «faster aspart» insulin has a pharmacological profile noted for its faster absorption and onset of action, and increased early availability, resulting in improved blood glucose control after meals. The main objective of the study was to analyse the efficacy of «faster aspart» vs. «insulin aspart» in children and adolescents with DM1 on sensor-augmented pump treatment. Multicentre, longitudinal and prospective analytical trial evaluating the use of faster aspart insulin for three months in children with T1DM with MiniMed640G® sensor-augmented pumps previously treated with aspart insulin. At the beginning and end of the study the following variables were analysed for subsequent comparison: mean sensor glucose, percentage of time in range, hypoglycaemia and hyperglycaemia, area under the curve (AUC) < 70 and > 180 mg/dL, mean sensor glucose pre and postprandial in main meals, daily insulin requirements, basal/bolus percentage, and HbA1c. Acute complications, adverse events and satisfaction survey were assessed. The study included 31 patients with a mean of 13.49 ± 2.42 years of age and with T1DM of 7.0 ± 3.67 years of onset. The use of faster aspart was associated with lower time in hyperglycaemia > 180 mg/dL (25.8 ± 11.3 vs. 22.4 ± 9.5; p = 0.011) and > 250 mg/dL (5.2 ± 4.9 vs. 4.0 ± 3.6; p = 0.04), lower AUC > 180 mg/dL (10.8 ± 6.5 vs. 9.3 ± 6.1; p = 0.03), and increased time in range (71.4 ± 10.0 vs. 74.3 ± 9.2; p = 0.03). No significant changes in hypoglycaemia, HbA1c, insulin requirements, and basal/bolus percentages were detected. Faster aspart was safe and well-evaluated by patients and caregivers. Faster aspart achieves better glycaemic control by increasing glucose time in range in children and adolescents with T1DM on treatment with sensor-augmented pumps.

9 July 2025 in JMIR Pediatrics and Parenting
Verified
Journal Article
Open access
AAAntonio de Arriba-Muñoz
Antonio de Arriba-Muñoz
EMElisa Civitani Monzón
Elisa Civitani Monzón
MFMaria Pilar Ferrer
Maria Pilar Ferrer
MFMarta Ferrer-Lozano
Marta Ferrer-Lozano
SPSilvia Quer Palomas
Silvia Quer Palomas
LLLuis Luque
Luis Luque
Background: Caregivers of children living with type 1 diabetes (T1D) face multiple challenges that significantly impact their mental health and quality of life. The well-being of caregivers directly affects the management of the child’s condition. The Adhera Caring Digital Program (ACDP) is a comprehensive, digitally delivered program, designed to support family caregivers in enhancing self-management and well-being. This study aims to assess how the ACDP influences caregivers’ mood, emotional well-being, and health-related quality of life within the context of T1D. Objective: This study aimed to evaluate the impact of ACDP on caregivers’ psychological well-being and caregiving outcomes. Methods: This was a two-step, prospective, mixed methods study targeting caregivers of children living with T1D who were under the care of a pediatric endocrinologist at Miguel Servet Children’s University Hospital in Zaragoza, Spain. In substudy 1 (SS1), qualitative and quantitative data were collected to optimize the ACDP. In substudy 2 (SS2), caregivers used the optimized ACDP for three months. Psychometric assessments were conducted at baseline and follow-up to evaluate positive mood states, general well-being, self-efficacy, and lifestyle behaviors. This paper focuses on SS2. Results: Ninety caregivers participated in SS2. Positive affect significantly increased (P<.001), and negative affect decreased (P<.001) on the Positive and Negative Affect Schedule (PANAS). Depression, anxiety, and stress scores were reduced (P<.001) on the Depression, Anxiety and Stress Scale-21 Items (DASS-21). General well-being, measured by the Mental Health Continuum-Short Form (MHC-SF) and self-efficacy, assessed using General Self-Efficacy Scale (GSE), improved significantly (P<.001). Health-related quality of life (HrQoL) scores and Mediterranean Diet Quality Index scores increased modestly (P=.03, and P=.04, respectively). Conclusions: The ACDP intervention improved caregivers’ psychological well-being and self-efficacy. These findings highlight the potential of digital solutions to support caregiver mental health and positively influence diabetes management. Future research should explore long-term outcomes and scalability.

3 November 2023 in Endocrine Practice
Verified
Journal Article
Closed access
MSMaría José Sánchez-Malo
María José Sánchez-Malo
JSJuan Hidalgo Sanz
Juan Hidalgo Sanz
MLMarta Ferrer Lozano
Marta Ferrer Lozano
JAJose Ignacio Labarta Aizpún
Jose Ignacio Labarta Aizpún
AAAntonio de Arriba-Muñoz
Antonio de Arriba-Muñoz